louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05034614: Pap Smear Collection With the Papette Brush
Official title: Pap Smear Collection With the Papette Brush: A Pragmatic Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cervical Cancer Screening
Keywords: Pap Smear Collection
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2021-09-05
Enrollment: 756
Sex: FEMALE
Minimum age (years): 21
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This research study is comparing Pap smear collection techniques using the Papette brush to traditional spatula and cytology brush for cervical cancer screening

Detailed description: At the investigators institution the investigators have been using both the traditional spatula and cytology and the Papette brush for Pap smear collection. The investigators will be comparing adequacy of sample rates, provider perceived pain and bleeding and overall satisfaction with each collection technique.

Eligibility criteria: Inclusion Criteria:

* Adult women, aged 21-64 years old.
* Have given consent for medical records to be accessed.
* Who will have a Pap smear exam in CIM from July 2021 through June 2022.

Exclusion Criteria:

* Women, age \< 21 or \> 64.
* Has vaginal spotting present during cervical sampling.
* Did not give consent to have medical records accessed.

Primary outcomes:
measure: Specimen Adequacy
timeFrame: Baseline
Secondary outcomes:
measure: Cervical Bleeding With Collection
timeFrame: Baseline
measure: Collection Time
timeFrame: Baseline
measure: Perceived Pain
timeFrame: Baseline
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Danielle O'Laughlin, PA-C, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05873114: Comparison of MET vs Mobilization in Management of Post-partum Backache in Females (NVD) and Cesarean Section Delivery
Official title: Comparison of Effects of Muscle Energy Technique (MET) vs Mobilization in Management of Post-partum Backache in Females With Normal Vaginal Delivery (NVD) and Cesarean Section Delivery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cesarean Section Complications
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2023-05-24
Enrollment: 50
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Effectiveness Comparison of Effects of Muscle Energy Technique (MET) vs Mobilization in Management of Post-partum Backache in Females With Normal Vaginal Delivery (NVD) and Cesarean Section Delivery


Eligibility criteria: Inclusion Criteria:

* Subjects with age group 20 to 40 year.
* low back pain and disability after normal vaginal delivery or c-section delivery will be included.

Exclusion Criteria:

* Subjects who had neurological deficit.
* spinal tumors, scoliosis
* underwent spinal surgery
* prolapsed intervertebral disc with or without radiculopathy will be excluded.

Primary outcomes:
measure: NPSR
timeFrame: 6 Months
measure: Owestry
timeFrame: 6 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Chaudary Muhammad Akram Teaching Hospital, Azra Naheed Medical College, Superior University
state: Punjab
Study officials:
References:
Clinical trial NCT02957214: Effects of an Intervention Program Based on Pain Education in Patients With Chronic Pelvic Pain
Official title: Prospective Controlled Study of the Effects of an Intervention Program Based on Pain Education in Pain Activity Patterns and Brain Connectivity in Patients With Chronic Pelvic Pain by Magnetic Resonance Images
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pelvic Pain
Lead sponsor: University of Valencia
Sponsor class: OTHER
First posted: 2016-11-06
Enrollment: 15
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to obtain imaging biomarkers based on changes in activity patterns and changes in brain connectivity obtained with the analysis of functional magnetic resonance imaging (fMRI) and tractography that are related to chronic pelvic pain


Eligibility criteria: Inclusion Criteria:

* Age between 18 and 55 years
* Chronic pelvic pain diagnosis
* Pain duration \> 6 months
* Average pain intensity ≥ 6 during the previous week

Exclusion Criteria:

* Suspected or knowledge of actual organic pathology that requires medical or surgical treatment
* Psychiatric illness: major depression, bipolar syndrome...
* Patients with significant cognitive deficits
* Have pacemaker, metal prostheses or hearing aids incompatible with MRI
* Severe traumatic brain injury
* Previous cranial surgeries
* History of alcoholism
* Do not sign informed consent

Primary outcomes:
measure: Study Functional Magnetic Resonance Image (fMRI)
timeFrame: At day 1
measure: Study Functional Magnetic Resonance Image (fMRI)
timeFrame: Between 7 and 31 days later randomly
measure: Study Functional Magnetic Resonance Image (fMRI)
timeFrame: At 6 months of completing the education program
Secondary outcomes:
measure: numerical rating scale NRS
timeFrame: Day 1 and at 6 months of completing the education program
measure: Multidimensional Pain Inventory (MPI) - Interference Scale
timeFrame: Day 1 and at 6 months of completing the education program
measure: Oswestry Disability Index (ODI)
timeFrame: Day 1 and at 6 months of completing the education program
measure: Hospital Anxiety and Depression Scale (HADS)
timeFrame: Day 1 and at 6 months of completing the education program
measure: Pain Catastrophizing Scale
timeFrame: Day 1 and at 6 months of completing the education program
measure: Tampa Scale for Kinesiophobia-11
timeFrame: Day 1 and at 6 months of completing the education program
measure: Female Sexual Function Index
timeFrame: Day 1 and at 6 months of completing the education program
Other outcomes:
Locations:
city: Valencia
country: Spain
facility: Rafael Torres Cueco
Study officials:
name: Rafael Torres-Cueco
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05799014: The Effectiveness and Safety of Electromagnetic Navigation Real-time Guided Percutaneous Lung Biopsy
Official title: The Effectiveness and Safety of Percutaneous Lung Biopsy Guided by Electromagnetic Navigation Real-time Positioning Technology
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Peripheral Lung Lesions
Lead sponsor: China-Japan Friendship Hospital
Sponsor class: OTHER
First posted: 2023-04-05
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The goal of this clinical trial is to evaluate the diagnostic efficacy and safety of percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology in peripheral lung lesions. The main question it aims to answer are: the effectiveness and safety of percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology.

Participants will undergo CT-guided percutaneous lung biopsy or percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology.


Eligibility criteria: Inclusion Criteria:

* Age 18-80 years old
* Imaging examination showed peripheral lung lesions
* Selected patients need to complete routine preoperative examinations such as blood routine examination, coagulation function, electrocardiogram, chest CT, etc
* There is no contraindication for puncture biopsy
* Good compliance, able to cooperate with research and observation
* Fully informed of the purpose and method of the study, agreed to participate in the study, and signed the informed consent form

Exclusion Criteria:

* Severe cardiopulmonary insufficiency, extreme weakness and intolerance of patients
* The patient is allergic to lidocaine and midazolam
* The site to be biopsied has a high risk of bleeding such as bronchial artery penetration or suspected lung metastasis of renal cancer
* Unstable angina pectoris, congestive heart failure, severe bronchial asthma
* The patient did not agree to participate in the study
* Participation in other studies within three months without withdrawal or termination will affect the observation of this study
* The researcher believes that there is any person who is not suitable for the selection

Primary outcomes:
measure: Diagnostic accuracy of percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology for diagnosis of pleural effusion.
timeFrame: 7 days after the lung biopsy
Secondary outcomes:
measure: Operation time
timeFrame: during the operation of lung biopsy
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06859814: Value of Infection Control Programs on Infection Associated with Urinary Tract Catheterization in Sohag University Hospital
Official title: Value of Infection Control Programs on Infection Associated with Urinary Tract Catheterization in Sohag University Hospital
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: UTI
Keywords: UTI
Urinary catheterization
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2025-03-05
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The aim of this study is to evaluate the effectiveness of an infection control program implemented at Sohag University Hospital in reducing the incidence of catheter-associated urinary tract infections (CAUTIs) among patients requiring urinary catheterization.


Eligibility criteria: Inclusion Criteria:

Adult patients (≥ 18 years) who are catheterized during their hospitalization. Patients who provide informed consent to participate in the study.

Exclusion Criteria:

Patients with a known history of urinary tract infections prior to hospitalization.

Patients who have indwelling catheters for more than 14 days before the study. Patients with urinary tract anomalies or other conditions that may affect infection rates.

Primary outcomes:
measure: Incidence of CAUTIs:
timeFrame: one month
Secondary outcomes:
measure: Length of Hospital Stay:
timeFrame: one month
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University Hospitals
Study officials:
References:
Clinical trial NCT00285714: 3D Imaging of Hard and Soft Tissue in Orthognathic Surgery
Official title: An Analysis of the Clinical Applicability of a Three-Dimensional Imaging Platform Used to Register the Influence of Orthognathic Surgery on Facial Hard and Soft Tissue in Patients With Congenital Maxillofacial Deformities.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Craniofacial Abnormalities
Maxillofacial Abnormalities
Cleft Lip
Cleft Palate
Keywords: 3D computer assisted imaging
maxillofacial surgery
cephalometry
normative value
Lead sponsor: Radboud University Medical Center
Sponsor class: OTHER
First posted: 2006-02-02
Enrollment: 450
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The primary objective of this clinical trial is to assess the influence of orthognathic surgery on facial soft tissue, such as changes (volume, linear, angular) of facial hard and soft tissue, in three dimensions, so enabling the setup of 3D normative value tables.


Eligibility criteria: Inclusion Criteria:

* Dysgnathic deformity
* Caucasian
* \> 15 years
* No history of orthognathic surgery
* Informed Consent

Exclusion Criteria:

* \< 15 years
* History of Orthognathic surgery
* Not Caucasian

Primary outcomes:
measure: All changes (volumetric, linear or angular) of facial hard and soft tissue caused by orthognathic surgery at 1 months, 6 months, 12 months and 24 months.
Secondary outcomes:
measure: All postoperative changes in functionality at 1 year
measure: patients' satisfaction of facial proportions at 1 year
measure: surgeons' satisfaction of the 3D planning platform at 1 month
Other outcomes:
Locations:
city: Arnhem
country: Netherlands
facility: Rijnstate Hospital
city: Ede
country: Netherlands
facility: Hospital Gelderse Vallei
city: Nijmegen
country: Netherlands
facility: Radboud University Nijmegen Medical Centre
Study officials:
affiliation: Radboud University Medical Center
name: Stefaan J Bergé, Prof, MD, DMD, PhD,
role: STUDY_DIRECTOR
affiliation: Radboud University Medical Center
name: Filip AC Schutyser, MsC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02825914: CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)
Official title: CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colitis, Ulcerative
Inflammatory Bowel Diseases
Keywords: glycopeptides
human microbiome
caseinomacropeptide
whey protein
dietary proteins
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2016-07-07
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Casein glycomacropeptide (CGMP) has anti-inflammatory properties in experimental rodent colitis and using human in vitro inflammation models. Its use as a food ingredient has proven safe and with no influence on dietary intake. In a pilot study the investigators found, that orally administered CGMP seems to have a beneficial effect comparable to that of mesalazine in active distal ulcerative colitis.

The investigators wish to evaluate the effects in a larger group of patients with active ulcerative colitis by studying the clinical effects and assessing the anti-inflammatory and microbiome modulating properties.


Eligibility criteria: Inclusion Criteria:

* ulcerative colitis (verified by mucosal histology and endoscopy)
* Clinically active ulcerative colitis (SCCAI ≥ 3)

Exclusion Criteria:

* Endoscopically inactive disease (Endoscopic Mayo Score of 0)
* Lactose or milk protein intolerance
* Celiac disease
* Not able to understand or speak Danish.
* Pregnant or nursing.
* Growth of pathogenic bacteria in stool culture from 4 weeks before and until randomization (Salmonella, Campylobacter, Yersinia or Clostridium Difficile.)

Primary outcomes:
measure: Endoscopic remission
timeFrame: 12 weeks
measure: Clinical remission
timeFrame: 12 weeks
measure: Clinical Response
timeFrame: 12 weeks
measure: Fecal inflammatory marker
timeFrame: 12 weeks
Secondary outcomes:
measure: Endoscopic response
timeFrame: 12 weeks
measure: Steroid-free remission
timeFrame: 12 weeks
measure: Clinical remission at follow-up
timeFrame: 26 weeks
Other outcomes:
Locations:
city: Aarhus C
country: Denmark
facility: Department of medicine V (Hepatology and Gastroenterology)
Study officials:
affiliation: University of Aarhus
name: Hendrik A Vilstrup, Professor
role: STUDY_CHAIR
References:
Clinical trial NCT02251314: Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma
Official title: The Utility and Relevance of Exome Sequence Analysis and Circulating Tumour DNA in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Melanoma
Keywords: BRAF mutant melanoma
circulation tumour DNA
tumour heterogeneity
liquid biopsy
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2014-09-29
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: UHN patients with BRAF mutant melanoma

Brief summary: Despite recent advances in cancer treatment, little impact has been made on curing as opposed to controlling cancers over the last several decades. Part of the problem is that investigators have an incomplete understanding of how tumours behave as they evolve and in response to treatment. In this trial, the investigators hope to better understand the evolution of BRAF melanoma in response to drugs a patient may have received such as vemurafenib or dabrafenib. Importantly, the investigators want to understand how the tumours evolve resistance to these drugs and whether this can be predicted through blood tests, in particular of the circulating tumour DNA.

Detailed description: Study population: BRAF mutant melanoma patients

Pre-mortem bloods will be taken from the patient on three occasions at one to thirty days apart from each other, with the first blood draw taking place on the patient's first clinic visit. Six 7 ml EDTA and one 6 ml SST vacutainers of blood (a total of approx. 50 ml of blood) will be taken from the patient.

When death is expected within the next 48-72 hours, the Medical Oncologist/ Radiation Oncologist/ Hematologist OR delegate will revisit the RAP process with the patient and/or family/substitute decision maker to ensure that they are still in agreement. The patient and the families will also be provided with an additional consent form for participation including blood sampling.

Eligibility criteria: Inclusion Criteria:

UHN adult patient with BRAF mutant melanoma

Exclusion Criteria:

Non BRAF mutant melanoma patient Pediatric patient Non-UHN patient

Primary outcomes:
measure: Percentage correlation between circulating tumour DNA and metastatic sites
timeFrame: 3 years
Secondary outcomes:
measure: Time to death
timeFrame: 2 years
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Princess Margaret Cancer Centre
state: Ontario
Study officials:
affiliation: Princess Margaret Cancer Centre
name: Anthony Joshua, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02775214: Conventional Direct Laryngoscopy Vs. Video Laryngoscopy With The C-MAC For Pyloromyotomy
Official title: Conventional Direct Laryngoscopy Vs. Video Laryngoscopy With The C-MAC For Pyloromyotomy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Pyloric Stenosis
Intubation, Pediatric
Keywords: Storz C-MAC
direct laryngoscopy
pyloromyotomy
rapid sequence
Lead sponsor: Indiana University
Sponsor class: OTHER
First posted: 2016-05-17
Enrollment: 62
Sex: ALL
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of this study is to compare two different ways of placing breathing tubes for surgery. Both ways are used currently to place breathing tubes and are safe and effective. This study seeks to determine if one way is better than the other for infants with pyloric stenosis.

Detailed description: Specific aims of this study include determining if there is a difference in the desaturation rates of the two different intubation techniques- Direct Laryngoscopy and the C-MAC video laryngoscope. Also is there a difference in intubation success between the two techniques, does intubation success vary with different training levels, and does desaturation rate differ among training levels.

Eligibility criteria: Inclusion Criteria:

* Need general anesthesia for pyloromyotomy procedure
* Have been informed of the nature of the study and informed consent has been obtained from the legally responsible guardian

Exclusion Criteria:

* Abnormal/difficult airway
* Allergy to succinylcholine and/or propofol

Primary outcomes:
measure: Number of Participants Who Had Desaturation Below 80% During Intubation
timeFrame: During intubation attempt (less than two minutes)
Secondary outcomes:
Other outcomes:
Locations:
city: Indianapolis
country: United States
facility: Riley Hospital for Children at IU Health
state: Indiana
Study officials:
affiliation: Sponsor-Investigator
name: Nicole Horn, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00965614: To Validate the Specific Patterns of Magnetocardiography, a Non-invasive Non-contact Examination for Patients With Ischemic Heart Disease or Cardiac Arrhythmia
Official title: To Validate the Specific Patterns of Magnetocardiography, a Non-invasive Non-contact Examination for Patients With Ischemic Heart Disease or Cardiac Arrhythmia
Study type: EXPANDED_ACCESS
Overall status: AVAILABLE
Conditions: Arrhythmia
Keywords: diagnose cardiac arrhythmia and CAD.
we'll try to establish the specific model to detect and diagnose cardiac arrhythmia and CAD.
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2009-08-25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT

Brief summary: ECG is one of the most important non-invasive method to diagnose CAD and arrhythmia. However, clinically it still has its limitation. Because the electrical field could induce a magnetic field, the newly developed non-contact technique, magnetocardiography, was established to detect the local magnetic field component of the heart. It is safe and more convenient. In this study, we try to define and validate the magnetocardiographic patterns in the patients with cardiac arrhythmias or ischemia.


Eligibility criteria: Patient enrollment:

* patients older than 18 years old,
* having received 1) 12-lead ECG examination for suspected cardiac arrhythmias or 2) stress tests for suspected coronary artery disease, will be invited.
* The patients who have medical devices made of metallic or magnetic material (ex. pacemaker, mechanical valve and arthroplasty) will be excluded to prevent the experimental bias.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: